Cartalax is a synthetic tetrapeptide bioregulator consisting of the sequence Ala-Glu-Asp-Leu (AEDL), developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Belonging to the same “Khavinson cytomedin” class as Epithalon (AEDG, pineal), Cortagen (AEDP, cortex), and Pancreagen (KEDW, pancreatic), Cartalax is the tetrapeptide identified by Khavinson and colleagues as the cartilage / connective tissue peptide bioregulator. The compound is proposed to function through tissue-specific gene expression modulation in chondrocyte and connective tissue cell populations. Cartalax has been investigated in the Russian academic literature (Bulletin of Experimental Biology and Medicine; Khavinson and colleagues) for chondrocyte gene expression, extracellular matrix biology, and age-associated cartilage cell function in preclinical research models. Like other Khavinson short-peptide bioregulators, Cartalax is studied primarily as a research tool for tissue-specific short-peptide pharmacology rather than as a defined receptor agonist.

Benefits (Research Focus)

• Chondrocyte gene expression research — studied for short-peptide bioregulator effects on cartilage cell populations

• Extracellular matrix biology — investigated for collagen and proteoglycan gene expression in connective tissue research models

• Khavinson SAR research — explored alongside other Khavinson short-peptide bioregulators for structure-activity studies

• Tissue-specific peptide signaling — examined as a “cytomedin” class compound for tissue-selective gene expression research

• Age-associated cartilage research — researched for chondrocyte biology endpoints in aged tissue research models

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.